Novartis AG ADR (NVS)vsVivos Therapeutics Inc (VVOS)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
VVOS
Vivos Therapeutics Inc
$0.18
+1.32%
HEALTHCARE · Cap: $3.75M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 271132% more annual revenue ($56.69B vs $20.90M). NVS leads profitability with a 22.5% profit margin vs -121.8%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
VVOS
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Margin of Safety
-5.4%
Fair Value
$1.47
Current Price
$0.18
$1.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Revenue surging 34.9% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1600.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : VVOS
The strongest argument for VVOS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 34.9% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : VVOS
The primary concerns for VVOS are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a value stock while VVOS is a hypergrowth play — different risk/reward profiles.
VVOS carries more volatility with a beta of 6.00 — expect wider price swings.
VVOS is growing revenue faster at 34.9% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 31/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Vivos Therapeutics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Vivos Therapeutics, Inc., a medical technology company, is dedicated to developing and commercializing treatment alternatives for patients with sleep-disordered breathing, such as mild to moderate obstructive sleep apnea (OSA). The company is headquartered in Highlands Ranch, Colorado.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?